Portable Diagnostic Device Development

This AI-powered ultrasound diagnoses pulmonary tuberculosis (TB) 9% better than human experts. A recent study at ESCMID Global 2025 revealed that the ULTR-AI suite significantly outperforms human doctors in diagnosing TB. At first glance, 9% seems small. But in healthcare, that's the difference between thousands of lives saved. Here's why this innovation excites me: 1. TB is still rising and access remains the biggest barrier Despite global efforts, TB cases rose 4.6% from 2020-2023. In high-burden regions, expensive equipment and specialist shortages mean 40% of patients never return for results. 2. ULTR-AI sets new accuracy standards With 93% sensitivity and 81% specificity, it beats WHO standards and catches early TB signs that experienced doctors might miss. 3. Proven in resource-limited settings Tested in Benin with 504 patients (38% TB-positive), it maintained performance despite power cuts and limited connectivity. 4. Mobile diagnostics for the hardest-to-reach patients By connecting portable ultrasound to smartphones, ULTR-AI eliminates the need for fixed infrastructure - a game-changer for rural communities. 5. Solving the follow-up gap Once integrated into an app, patients get instant results, addressing the 40-60% loss-to-follow-up issue I've seen across health systems. I've spent two decades in healthtech, and what impresses me most is that ULTR-AI addresses the entire diagnostic journey - from real-time results to overcoming infrastructure challenges. But the real test will be scaling this beyond controlled studies. The global diagnostics market is set to hit $150B by 2030 - and this might make a place for itself. What other health challenges do you think could benefit from smartphone-connected AI? #ai #healthcare #innovation #startups

🌿 Early Disease Detection in the Field? There's an App for That ! 📱🧬 - Potato late blight, caused by Phytophthora infestans, remains one of the most destructive plant diseases, with historical impact (e.g., Irish Famine) and major global agricultural losses. - Traditional detection methods like PCR and LAMP are sensitive but require lab infrastructure, skilled personnel, and long processing times and limiting their use in the field. - The need for fast, specific, on-site diagnostic tools is important for early-stage detection before symptoms appear, to guide timely intervention.   In this preprint from a team from China Agricultural University shows how they developed a smartphone-integrated, CRISPR-based diagnostic system that uses: - Microneedle patches for 1-minute DNA sampling - RPA (Recombinase Polymerase Amplification) – a rapid, isothermal DNA amplification method –> increases the amount of target DNA - CRISPR-Cas12a for sensitive, highly specific detection -> Cas12a finds it, binds it, and will be cutting up nearby probes. - A portable fluorescence imaging device powered by a smartphone -> more fluorescence = more target DNA = positive sample.   Detection was possible up to two days before visible symptoms appeared. The system identified P. infestans with no cross-reactivity and detected as little as 2 pg/μL of DNA, comparable with lab-based PCR. Advantages of this approach - Who needs a lab? The entire process - from leaf sampling to result interpretation - takes under 90 minutes and costs less than $110 USD, making it accessible for farmers and low-resource environments. Rapid, field-deployable, Low cost This isn't just about potatoes. Combining molecular biology, low-cost engineering, and mobile technology can transform plant disease diagnostics across agriculture. Think "lab-on-a-leaf," powered by your phone - Smartphone-integrated, real-time results. Read the full paper: https://lnkd.in/eU2JdzsR #CRISPR #RPA #PlantHealth #PrecisionAgriculture #AgTech #SyntheticBiology #CropProtection #MolecularDiagnostics

“UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity. "DNA detection is in the center of bioengineering," says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences. Ping is an assistant professor of mechanical and industrial engineering, an adjunct assistant professor in biomedical engineering and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. "Everyone wants to detect the DNA at a low concentration with a high sensitivity. And we just developed this method to improve the sensitivity by about 100 times with no cost." With traditional detection methods, he says, "The challenge is basically finding the needle in a haystack." There are lots of molecules present in a sample that aren't the target DNA that can interfere with the result. That's where this method is different. The test sample is put within an alternating electric field. Then, "We let the DNA dance," he says. "When the strands of DNA dance, they have a specific oscillation frequency." Researchers can then read samples to see if there is a molecule moving in a way that matches the movement of the target DNA and easily distinguish it from different movement patterns. This even works when there is a very low concentration of the target DNA. This new method has huge implications for speeding up disease detection. First, because it is so sensitive, diagnoses can happen at earlier stages of a disease progression, which can greatly impact health outcomes. Also, this method takes minutes, not days, weeks or months, because it's all electric. "This makes it suitable for point of care," he says. "Usually, we provide samples to a lab and they can provide the results quickly or slowly, depending on how fast they go, and it can take 24 hours or longer." Another benefit: it's portable. Ping describes the device to be similar in size to a blood sugar test tool, which opens the doors to improvements in health on a global scale. "It can be used at places where resources are limited." Ping is excited about the breadth of possible applications for this discovery, saying, "The nano-mechanoelectrical approach can be also integrated with other bioengineering technologies, like CRISPR, to elucidate nucleic acid signaling pathways, comprehend disease mechanisms, identify novel drug targets and create personalized treatment strategies, including microRNA-targeted therapies." Xiaoyu Zhang, a graduate research assistant from Ping Lab, will deliver an oral presentation relevant to this study at the Biomedical Engineering Society annual meeting on October 13, 2023 in Seattle, WA.” https://lnkd.in/g9Cjgv46

TB or not TB? For nearly 150 years, #tuberculosis diagnosis has relied heavily on phlegm - a sample that is difficult to collect, unpleasant to handle, and not always easy for children, older adults, or very sick patients to produce. ▪️ A new portable molecular test, #MiniDock #MTB, developed by the Chinese company Pluslife, may help change that. ▪️ The test can use either phlegm or a simple tongue swab, then scans for #TB bacterial DNA. According to recent research, it is faster, easier to use, more affordable, and accurate enough to meet World Health Organization targets. ▪️ This matters because TB remains the world’s deadliest #infectiousdisease, killing more than a million people each year. Delayed or missed diagnosis means patients get sicker, treatment starts later, and transmission continues. ▪️ There are still limitations. The test may need improvement for detecting very early disease, and it does not identify #drugresistant TB without additional testing. 💡 Still, this feels like an important step toward making high-quality TB testing more accessible, especially in communities where the burden is highest. Diagnostics save lives. 🗃️ See comments for link to NPR reference.

#India's Molbio Diagnostics🇮🇳 Deploys Decentralised Molecular Testing Solution Amid Ongoing #Ebola Outbreak in #Africa🌍 On 17 May, the World Health Organization(#WHO) declared the ongoing Ebola outbreak in the Democratic Republic of the #Congo(DRC) and #Uganda a Public Health Emergency of International Concern(PHIC)🆘️ This 2026 Ebola outbreak caused by the rare Bundibugyo virus has resulted in 837 confirmed cases and 196 deaths☠️ across DRC & Uganda. DRC🇨🇩: 837 confirmed cases + 196 confirmed deaths. The outbreak is concentrated primarily in the eastern Ituri, North Kivu & South Kivu provinces, making it one of the largest and most complex outbreaks in the DRC's history🆘️ Uganda🇺🇬: 19 confirmed cases + 2 deaths. Most cases are linked to individuals crossing the border from DRC to seek treatment or due to localized secondary transmission🆘️ This outbreak is caused by the Bundibugyo virus with case fatality rates ranging from 30% - 55%🆘️ Unlike the more common Zaire ebolavirus, there is currently NO approved vaccine/specific antiviral treatment for the Bundibugyo strain🆘️ The ongoing #crisis is being heavily complicated by regional insecurity, active conflict zones & community mistrust. On 22 May, Molbio Diagnostics participated in the #emergency consultation convened by the WHO and the #Africa Centres for Disease Control and Prevention(Africa CDC), bringing together key stakeholders to accelerate the #research, #development, and deployment of decentralised diagnostic solutions to support #outbreak response efforts. Molbio has developed a "real-time" PCR test capable of detecting Ebola disease caused by ALL 3 outbreak-associated viruses: Ebola virus, Sudan virus & Bundibugyo virus. ✅️Designed for decentralised settings, the test runs on Molbio’s near-patient portable Truenat® platform and delivers results in approximately 1 hour, enabling faster clinical decision-making & timely public health intervention ✅️Compact, lightweight, and solar-powered(via Truelux), it is designed specifically for field use and remote clinics without complex laboratory infrastructure ✅️The Truelab Micro PCR Analyzer can run various tests(including TB, malaria, dengue)using a single portable system ✅️The automated extraction + interpretation process requires minimal training for operators Molbio is currently working closely with the WHO, the Africa CDC, and local authorities to validate the test on clinical specimens urgently. Initial deployment has commenced, and test kits have already reached affected regions in Uganda and the DRC. Molbio’s flagship Truenat® real-time #PCR platform is globally recognized & endorsed by the WHO, enhancing affordable, high-quality infectious disease management worldwide🌍 Kudos👏 Sriram Natarajan Chandrasekhar Nair Sangeetha Sriram Darshan Karekar Kuldeep Singh Sachdeva Manan Khokhani Shiva Sriram Sarah Oliveira Fernandes Indraneil Borkakoty Reeti Desai Hobson, MPH Seema Ansari #MadeInIndia #VocalForLocal 📍

Application of AI in Lab-on-a-Chip for Lung Cancer Diagnosis Artificial intelligence (AI) is transforming the field of cancer diagnosis, and one of the most promising applications is lab-on-a-chip (LOC) technology for lung cancer diagnosis. LOC systems miniaturize laboratory processes onto a single chip, enabling rapid and cost-effective diagnostic tests. By integrating AI, these systems become more powerful and can detect lung cancer faster and more accurately at early stages. Lung cancer is one of the leading causes of cancer death worldwide and is often diagnosed too late for effective treatment. AI-enhanced LOC devices offer a new cancer diagnosis solution by analyzing biomarkers in biological samples such as blood or tissue in real time. These devices can use AI algorithms to detect and analyze specific proteins, DNA mutations, or microRNAs associated with lung cancer. In particular, machine learning algorithms can not only learn to recognize patterns from large data sets and detect cancer cells with high accuracy, but also do so at early stages when clinical symptoms may not be obvious. In addition, AI can also enable real-time data analysis, thereby enhancing the diagnostic capabilities of LOC. With the ability to process large amounts of data, AI helps overcome the challenges of traditional diagnostic methods, which can be time-consuming and require specialized equipment. We believe that the combination of AI and LOC truly enables portable point-of-care testing, as this can significantly improve the accessibility and affordability of diagnostic methods, especially in resource-limited settings. In summary, the use of AI in lung cancer diagnostic lab-on-a-chip systems not only provides faster and more accurate diagnosis, but also has the potential to revolutionize lung cancer detection methods, bringing hope for early intervention of lung cancer and improved survival rates. This synergy of AI and LOC technology marks a major advancement in personalized medicine, bringing us closer to more effective and patient-specific treatment options. The main advantages of AI-based lab-on-a-chip for lung cancer diagnosis include: (1) Early lung cancer detection (2) Portable point-of-care testing (3) Improved diagnostic accuracy through AI (4) Improved accessibility and affordability References [1] Huixian Zhang et al., Translational Cancer Research 2021 (doi: 10.21037/tcr-20-3398) [2] J Luis Espinoza et al., J Clinical Medicine 2020 (https://lnkd.in/eqVksUir) #AIinHealthcare #LabOnAChip #LungCancerDiagnosis #CancerDetection #PrecisionMedicine #BiomedicalInnovation #AIandMedicine #EarlyCancerDetection #PointOfCareTesting #HealthcareTech #MedicalBreakthrough #AIinBiotech #CancerResearch #InnovativeDiagnostics #AIandLOC #AIAdvances #BioTechRevolution #PersonalizedMedicine #MachineLearningInHealth #NextGenHealthcare

🚨 Revolutionizing Tuberculosis Diagnosis 🚨 Imagine a handheld device, no larger than a smartphone, capable of detecting tuberculosis (TB) from saliva, blood, or sputum in under an hour with unmatched accuracy. Tulane University researchers have just made this a reality. Why does this matter? Over 1 million children fall ill with TB each year, and over half go undiagnosed. Current diagnostic tools are expensive, invasive, and inaccessible to low-income, high-burden regions. This new device costs under $800, with individual tests being priced reasonably and affordably, bringing hope to resource-limited areas. By removing barriers to diagnosis, this breakthrough technology could significantly reduce TB’s global toll and ensure lifesaving treatment reaches those who need it most. 🌍 📚 Featured on the cover of Science Translational Medicine, this portable, cost-effective solution proves that innovation can be a driving force for global health equity. I am constantly inspired by our scientists and doctors as they make leaps forward in healthcare! What are your thoughts on the accessibility of life-saving technologies like this one? 💬 Please share below! And give your props to innovators Tony Hu and Brady Youngquist https://lnkd.in/gHJc4ABQ